|
Each Vial 5ml contains:
Composition:
Abciximab
.....................................................................2
mg
Indications :
Platelet aggregation inhibition as adjunct to
percutaneous
transluminal coronary angioplasty or atherectomy (PTCA).
Description:
Abciximab (c7E3) is a chimeric mouse-human monoclonal
antibody directed against the GP IIb/IIIa receptor; its
mechanism of
action is thought to be steric hindrance of the receptor
itself as
opposed to direct binding to the RGD binding site of the
receptor. It also inhibits the vitronectin (av
b3)receptor, which mediates both
platelet coagulation as well as endothelial and vascular
smooth
muscle cell proliferation.
Dosage:
0.25 mg/kg administered 10-60 minutes before the start
of PTCA ` followed by a continuous I.V.. Injection of 10
mcg/min.
for 12 hours.
Presentations:
Vial 5ml
MRP Retailer
Stockiest
19740.00 15792.00
14212.80
| 
